ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Last week saw a run of contract manufacturing deals in the pharmaceutical sector. Albany Molecular Research Inc. was selected by Biota Holdings, an anti-infectives drug company in Australia, to develop and manufacture laninamivir, an influenza antiviral. Biota is seeking to establish U.S. manufacturing of laninamivir, a second-generation neuraminidase inhibitor, to facilitate clinical trials in support of a New Drug Application with FDA. Meanwhile, Germany’s Agennix has contracted with Lonza for production of talactoferrin, currently in Phase III clinical trials for the treatment of non-small-cell lung cancer. Under the agreement, Lonza will produce commercial material at its microbial biologics facility in Kourim, Czech Republic. The project could lead to the approval of Lonza as a second manufacturer of talactoferrin after DSM. And Asahi Glass will invest $10 million in a new production line for tafluprost, the active ingredient in a glaucoma therapy marketed by Santen Pharmaceutical and Merck & Co. The plant will be built in Obama, Japan, and will double capacity for tafluprost, which Asahi Glass currently manufactures in Chiba, Japan.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X